PharmaCyte Biotech Files Definitive Proxy for Reverse Stock Split and 18.6% Potential Equity Dilution

summarizeSummary

PharmaCyte Biotech filed a definitive proxy statement seeking shareholder approval for a reverse stock split to avoid Nasdaq delisting and a significant increase in shares for its equity incentive plan, potentially diluting existing shareholders by 18.6%.

check_boxKey Events

• Shareholders to Vote on Reverse Stock Split

  The Board is seeking approval for a reverse stock split with a ratio between 1-for-1.1 and 1-for-100 to increase the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement, following a delisting notice received on December 1, 2025.

• Board Seeks Approval for 18.6% Potential Equity Dilution

  Shareholders will vote on an amendment to the 2022 Equity Incentive Plan to increase the number of shares available for awards by 2,000,000, representing approximately 18.6% potential dilution based on 10,735,649 outstanding shares.

• Auditor Change Follows Acquisition, Prior Material Weaknesses Noted

  The company's auditor changed from Marcum to CBIZ CPAs P.C. due to an acquisition. The filing notes that Marcum's prior audits identified material weaknesses related to insufficient segregation of duties of the CFO and management review controls.

• Annual Meeting Scheduled for March 30, 2026

  The definitive proxy statement sets the annual meeting date for March 30, 2026, where shareholders will vote on these critical proposals, including director elections and executive compensation.

auto_awesomeAnalysis

This definitive proxy statement outlines critical proposals for PharmaCyte Biotech's upcoming annual meeting, following a preliminary filing on February 27, 2026. The most significant proposal is a reverse stock split, with a ratio between 1-for-1.1 and 1-for-100, aimed at increasing the per-share price to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting. This indicates the company is facing significant pressure to maintain its exchange listing, a major concern for a micro-cap company. Concurrently, the company is seeking shareholder approval to increase the shares available for equity awards by 2,000,000, which represents a substantial potential dilution of approximately 18.6% based on current outstanding shares. This level of potential dilution is highly significant for a company of this market capitalization. Additionally, the filing details an auditor change from Marcum to CBIZ CPAs P.C., which occurred due to an acquisition, but also highlights previously identified material weaknesses in internal controls. Investors should closely monitor the outcome of these votes, particularly the reverse stock split and the equity plan amendment, as they have direct implications for the company's stock price, capital structure, and future financing capabilities.